A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
NCT07154745Phase 3Recruiting
- Lead sponsor
- Regeneron Pharmaceuticals (Industry)
- Enrollment
- 35 (estimated)
- Start date
- 11 Jun 2026
- Primary completion
- 18 Jan 2030 (estimated)
- Study completion
- 4 Dec 2031
- Last update posted
- 5 Aug 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None
- Arms
- 1
Interventions
- Pozelimab Drug
- Cemdisiran Drug
Conditions and primary outcome
- Paroxysmal Nocturnal Hemoglobinuria
Primary outcome
Percent change in Lactate Dehydrogenase (LDH) during TP (From baseline to week 28)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07154745.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07154745 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.